Market Performance and Context: Adma Biologics and Peer Overview
Adma Biologics (ticker ADMA) closed the trading session on Tuesday, 20 October 2026 at USD 11.23 per share, reflecting a 3.65 % rise over the preceding 24 hours. At the close of the session, the company’s market capitalisation stood at USD 2.4 billion, with a float of 223.8 million shares. During the last 24 hours, roughly USD 31.8 million worth of ADMA shares changed hands, a figure that underscores moderate liquidity for the stock.
The share price’s upward momentum is consistent with the longer‑term trend: since the close of September 2026, ADMA has gained 16.47 %. The 200‑day simple moving average, a commonly watched technical indicator, sits at USD 11.27, indicating that the recent price is only marginally below the medium‑term average. The firm’s 52‑week high, reached at USD 20.46 on 12 December 2025, and 52‑week low, at USD 7.21 on 26 March 2026, provide a reference frame for assessing potential upside and downside.
Peer Performance Snapshot
To contextualise ADMA’s movement, the following table summarises the 24‑hour performance of five peer securities.
| Ticker | 24‑h Change | Current Price | Market Capitalisation | Notable Highlights |
|---|---|---|---|---|
| DNOW | +3.38 % | USD 15.77 | USD 2.8 bn | GF score of 82 suggests solid operations; modest uptick in investor sentiment. |
| GPI | –1.21 % | USD 243.02 | USD 2.9 bn | P/E ratio of 10.3; recent decline modest relative to sector. |
| MARA | –1.99 % | USD 7.48 | USD 2.9 bn | SEC Rule 144 filing for 16,000 shares; recent Bitcoin transfers raise speculation on further disposals. |
| FRVO | –5.99 % | USD 9.29 | USD 2.9 bn | JPMorgan lowered price target amid renewables uncertainty; company remains active in geothermal projects. |
| ATRC | –0.96 % | USD 57.67 | USD 2.9 bn | P/E ratio of 267.03; slight decline, but valuation remains high. |
Adma Biologics: Business Focus
ADMA Biologics, Inc. is headquartered in Ramsey, United States, and specialises in the development and commercialisation of human plasma and plasma‑derived therapeutics for patients with compromised immunity. The firm’s product pipeline is designed to address unmet medical needs, positioning it within a niche yet critical segment of the biopharmaceutical market.
Analytical Takeaway
The modest 3.65 % increase in ADMA’s share price, coupled with its alignment to the 200‑day moving average, suggests a continuation of the current bullish trend, albeit within a relatively stable price band. When compared to its peers, ADMA’s performance is broadly in line with the sector’s moderate gains, particularly against DNOW’s similar uptick and the declines observed in GPI, MARA, FRVO, and ATRC. The firm’s robust market cap and steady float provide a solid foundation for further analysis of its long‑term growth prospects, especially as it navigates the competitive landscape of plasma‑derived therapeutics.
